Hello, everyone, and how are you today? We are doing just fine, thank you, especially now that things have quieted down on the Pharmalot campus. The short people have left for the local schoolhouse and gainful employment, respectively, and the official mascots are quietly dreaming of treats. As for us, we are firing up the trusty coffee kettle to brew a few cups of needed stimulation. Our preferences today are for peppermint mocha and butter pecan. Such a decision. Meanwhile, here are some tidbits to get you going. Hope today is a splendid and productive day. And, as always, do stay in touch. We appreciate your suggestions and tips …

A recent acquisition streak by Novartis (NVS) is pivoting the company toward new treatments that bear little resemblance to traditional drugs, The Wall Street Journal explains. The drug maker has spent nearly $15 billion in the past year to build its presence in cutting-edge areas of medical research, including gene therapy, or treatments that introduce new DNA into the body, and radiopharmaceuticals, which are drugs that carry radioactive particles to tumors for close-range radiotherapy.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy